Abstract

Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

Guidance development process 

How we develop NICE technology appraisal guidance 

Is this guidance up to date?

We reviewed the evidence in September 2018. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.